MO159: Serum Trimethylamine N-Oxide Level is Positively Associated with Aortic Stiffness Measuring by Carotid-Femoral Pulse Wave Velocity in Maintenance Haemodialysis Patients

Abstract

Abstract BACKGROUND AND AIMS Trimethylamine-N-oxide (TMAO) acts as an evident predictor for the prevalence of cardiovascular disease and increased incidence of major adverse cardiovascular events. Aortic stiffness predicts cardiovascular disease and is associated with ageing-associated vascular diseases. The aim of this study was to evaluate the relationship between serum TMAO levels and carotid-femoral pulse wave velocity (cfPWV) in chronic haemodialysis (HD) patients. METHOD A total of 115 patients with HD were enrolled in this study. cfPWV was measured using the SphygmoCor system. Patients with cfPWV >10 m/s were defined as the aortic stiffness group. Serum TMAO level was performed with high-performance liquid chromatography and mass spectrometry. RESULTS Forty-two HD patients (36.5%) had aortic stiffness and higher percentages of diabetes (P < .001), hypertension (P = .026), were of older age (P = .028) and had higher systolic blood pressure (P = .025), serum glucose level (P = .029) and TMAO levels (P < .001) compared to control group. After adjusting for factors significantly associated with aortic stiffness by multivariate logistic regression analysis, serum TMAO [odds ratio (OR): 1.010, 95% confidence interval (CI): 1.003–1.017, P = .003) and age (OR: 1.046, 95% CI: 1.007–1.088, P = .021) were independently associated with aortic stiffness in patients with chronic HD. After multivariable forward stepwise linear regression analysis also noted that serum TMAO level (β = 0.355, adjusted R2 change = 0.198, P < .001) was positively associated with cfPWV values in HD patients. CONCLUSION Serum TMAO level is an independent marker of aortic stiffness and is positively associated with cfPWV values in patients with chronic HD.